276 related articles for article (PubMed ID: 29940148)
1. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
[TBL] [Abstract][Full Text] [Related]
2. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
[TBL] [Abstract][Full Text] [Related]
5. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
[TBL] [Abstract][Full Text] [Related]
6. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
7. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
Front Immunol; 2020; 11():589997. PubMed ID: 33193421
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
[TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
10. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
12. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
[TBL] [Abstract][Full Text] [Related]
13. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
14. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J
Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792
[TBL] [Abstract][Full Text] [Related]
15. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
18. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
19. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
Kim AK; Gani F; Layman AJ; Besharati S; Zhu Q; Succaria F; Engle EL; Bhaijee F; Goggins MB; Llosa NJ; Pawlik TM; Yarchoan M; Jaffee EM; Simons HC; Taube JM; Anders RA
Cancer Immunol Res; 2019 May; 7(5):805-812. PubMed ID: 30902819
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
Suzuki H; Iwamoto H; Tanaka T; Sakaue T; Imamura Y; Masuda A; Nakamura T; Koga H; Hoshida Y; Kawaguchi T
Hepatol Int; 2024 Apr; 18(2):610-622. PubMed ID: 37864726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
